You're viewing our updated article page. If you need more time to adjust, you can return to the old layout.

ORIGINAL RESEARCH article

Front. Allergy, 23 January 2026

Sec. Food Allergy

Volume 7 - 2026 | https://doi.org/10.3389/falgy.2026.1737009

Specific IgE to tropomyosin increases the diagnostic accuracy of shrimp allergy

  • 1. Department of Clinical Epidemiology, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand

  • 2. Center of Excellence for Allergy, Asthma and Pulmonary Disease, Thammasat University, Pathum Thani, Thailand

  • 3. Division of Pediatrics, Chaophya Hospital, Bangkok, Thailand

  • 4. Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Thailand

  • 5. Division of Allergy and Clinical Immunology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

  • 6. Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand

Article metrics

View details

636

Views

61

Downloads

Abstract

Purpose:

Skin prick test (SPT) and the level of serum-specific IgE (sIgE) antibodies to shrimp have low specificity in the diagnosis of shrimp allergy. Measurement of sIgE to tropomyosin is available as a test, but the accuracy remains controversial. This study aims to evaluate the diagnostic accuracy of sIgE measurement to tropomyosin in the diagnosis of shrimp allergy and compare the diagnostic performance to SPT and sIgE to shrimp.

Methods:

Patients with a history of immediate reaction to shrimp allergy were recruited. All participants underwent SPT with commercial shrimp extract. Measurements of sIgE to shrimp and tropomyosin were carried out. An oral food challenge (OFC) with shrimp was performed to confirm the diagnosis.

Results:

Fifty symptomatic patients (mean age 27.3 years) with suspected shrimp allergy were evaluated. OFC confirmed allergy in 13 (26%) patients. Diagnostic modalities offered distinct advantages and limitations. Tropomyosin sIgE (rPen a 1) yielded superior specificity (91.9%) at the cost of sensitivity (23.1%), while extract-based tests (SPT and shrimp sIgE) provided better sensitivity (46.2%–61.5%) but lacked specificity (43.2%–51.4%). Implementing a two-step algorithm—combining SPT with tropomyosin sIgE—successfully optimized specificity to 94.6%. Nevertheless, given the suboptimal predictive values across all methods (PPV 25%–50%; NPV 73%–77%), these tools alone cannot safely guide management, and OFC remains essential.

Conclusion:

Measurements of sIgE to tropomyosin provided higher specificity and increased diagnostic efficiency than SPT and measurement of sIgE to shrimp for the diagnosis of shrimp allergy.

Introduction

Shrimp is a common cause of food allergy (1, 2). Symptoms can occur in a single organ such as the skin (e.g., urticaria and lip/tongue swelling), respiratory system (e.g., chest tightening and wheezing), gastrointestinal system (e.g., oral allergy syndrome and vomiting), or cardiovascular system (e.g., low blood pressure). In some cases, multiple organ system involvement occurs such as anaphylaxis in which urticaria and angioedema are the most common accompanying symptoms (3, 4). These reactions usually occur within 2 h after ingestion and involve an IgE-mediated mechanism.

Similar to other food allergies, the conventional investigation tools for immediate-type hypersensitivity reactions to shrimp are skin prick test (SPT), serum-specific IgE (sIgE) for food measurement, or both. Oral food challenge (OFC) is the gold standard tool to exclude or confirm a diagnosis but should be performed under specialist supervision because this procedure might induce a severe allergic reaction (5). However, SPT with shrimp commercial extracts and measurements of sIgE to shrimp have shown low specificities of <50% for a shrimp allergy diagnosis (6, 7). Hence, the definite diagnosis for shrimp allergy remains challenging.

An understanding of allergens, including their specific IgE-binding epitopes, and improvements in technology to produce recombinant allergens allow the development of component-resolved diagnosis (CRD). CRD detects IgE antibodies specific to entire allergenic proteins (components), providing a more precise diagnosis than whole extracts (8). CRD testing has demonstrated high specificity for food allergy diagnosis (e.g., cow's milk and egg) (9). However, reports on using CRD in the diagnosis of shrimp allergy are lacking.

Tropomyosin has been identified as the major shrimp allergen in several shrimp species including Penaeus aztecus (Pen a 1), Penaeus indicus (Pen i 1), Penaeus monodon (Pen m 1), Metapenaeus ensis (Met e 1), and Litopenaeus vanamei (Lit v1) (10, 11). Tropomyosin was shown to share immunodominant epitopes among all species of crustaceans (12). In silico analyses of Lit v 1 show numerous high-identity matches with tropomyosins from multiple shrimp and prawn species (13). A commercial test for measurements of serum IgE to recombinant tropomyosin (rPen a 1) is currently available. However, the accuracy remains controversial. Gámez et al. (14) reported a specificity of 77% for sIgE levels to rPen a 1. In contrast, Ayuso et al. (15) reported a specificity of only 45.5%. One significant factor contributing to the variation in shrimp sensitization is house dust mite (HDM) allergy. This is due to the cross-reactivity between tropomyosin in shrimp and house dust mite (16). It is important to note that Thailand is an HDM-endemic area (17). A small study in this population reported that 30% of patients with shrimp allergy had positive sensitization to HDM (18).

We aimed to evaluate the diagnostic accuracy of measuring sIgE antibodies to tropomyosin in the diagnosis of Litopenaeus vanamei shrimp allergy. We also aimed to compare its diagnostic performance with the results of SPT and the levels of serum-specific IgE antibody to shrimp using commercial testing and recombinant Litopenaeus vanamei IgE testing.

Materials and methods

Study participants

Patients with a history of immediate reaction to shrimp were recruited into a cross-sectional study; all participants were followed up at the Thammasat University Center of Excellence for Allergy, Asthma, and Pulmonary Disease. The immediate reaction was defined as ≥1 reported symptom of skin (e.g., urticaria and lip/tongue swelling), respiratory system (e.g., chest tightening and wheezing), gastrointestinal system (e.g., vomiting), or cardiovascular system (e.g., low blood pressure), which occurred within 2 h after consumption (19).

Patients with a history of delayed reactions or only subjective symptoms (e.g., pruritus) were excluded. We also excluded patients with an underlying disease, such as cardiovascular disease, or patients who did not complete the allergy testing.

The study was approved by the Institutional Review Board and the Ethics Committee of the Faculty of Medicine, Thammasat University. Written informed consent was obtained from the patients or parents if the patients were ≤18 years of age.

Skin prick test

SPT was performed with commercial shrimp extracts (ALK-Abello, New York, USA). Histamine 1 mg/mL and 50% glycerin were used as positive and negative controls, respectively. One drop of each reagent was applied to the volar surface of the forearm using a 1 mm single peak lancet by experienced nurses and read after 15‒20 min. The SPT result was defined as positive if the mean wheal diameter was ≥3 mm.

Measurement of IgE antibodies to shrimp and tropomyosin

Serum IgE to shrimp was measured using the f24 ImmunoCAP (Thermo Fisher Scientific, Uppsala, Sweden). The f24 ImmunoCAP provides a quantitative measure of specific IgE using an extract prepared from the following species: Penaeus monodon, Metapenaeopsis barbata, Pandalus borealis, and Metapenaeus joyneri. Specific IgE to tropomyosin was measured using a f351 recombinant Pen a 1 (rPen a 1; Thermo Fisher Scientific, Uppsala, Sweden). Serum IgE to shrimp and tropomyosin levels were considered positive if the level was ≥0.35 kUA/L.

Oral food challenge

The OFC was performed by administering increasing doses of 1, 2, 4, 8, 16, and 32 g of boiled shrimp (Litopenaeus vanamei) at 15–20 min intervals with a total amount of 63 g equal to approximately 15 g of shrimp protein (6). The OFC was performed and assessed by a team of experienced nurses and allergists. Emergency medications, such as epinephrine, antihistamine, steroids, and equipment, were prepared. During the OFC, the patients were monitored for vital signs, abnormal signs, and symptoms (e.g., urticaria and angioedema) before escalating each dose.

The OFC was discontinued if participants developed objective signs of IgE-mediated allergic reactions, in accordance with the well-established guidelines (20). A positive challenge required objective involvement of the skin, respiratory, gastrointestinal, or cardiovascular systems. Stopping criteria included the following: (1) generalized urticaria or progressive angioedema, (2) respiratory compromise (persistent cough, wheeze, stridor, voice change, dyspnea, or ≥20% reduction in peak expiratory flow), (3) repetitive vomiting or severe abdominal pain, or (4) cardiovascular compromise (hypotension or syncope). Anaphylaxis or persistent/recurrent objective symptoms affecting ≥2 organ systems were also considered positive. Isolated, mild, and transient symptoms (e.g., limited erythema or oral pruritus) were recorded but not considered sufficient to halt the test. Isolated throat tightness without objective signs led to reassessment and temporary delay only; the challenge was stopped and considered positive if symptoms persisted or progressed. Participants were observed for at least 2 h after the final dose.

Statistical analysis

Data were analyzed using STATA version 14.0. Demographic characteristics were described as numbers and percentages for categorical data, mean ± standard deviation (SD), or median interquartile range for continuous data, as appropriate. The diagnostic accuracy was calculated in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and efficiency. Efficiency was defined as the proportion of true positive and true negative results detected among the total number of participants who performed the test.

Results

Patient characteristics

Fifty patients participated in this study. The mean ± SD age was 27.3 ± 10.8 years, and the number of females was 36 (72.0%). The mucocutaneous symptoms including angioedema (60%) and urticaria (58%) were the most common clinical presentation, followed by respiratory symptoms (e.g., chest tightness; 40%) and gastrointestinal symptoms (e.g., vomiting; 18%), respectively (Table 1). Half of the patients reported mucocutaneous symptoms only while the other half reported multiple organ system symptoms. The presenting symptoms and demographics are presented in Table 1.

Table 1

Characteristics
Mean age (years), mean ± SD 27.3 ± 10.8
Gender
 Female 36 (72.0)
 Male 14 (28.0)
Atopic history
 Asthma 3 (6.0)
 Allergic rhinitis 23 (46.0)
 Atopic dermatitis 8 (16.0)
 Other food allergy 20 (40.0)
  Crab 16
  Squid 2
  Clams 2
  Wheat 2
Clinical manifestationsa
Skin/oral/mucosal tissue symptoms
Urticaria 29 (58.0)
Angioedema 30 (60.0)
Itching in the oral cavity 27 (54.0)
Respiratory symptoms
Nasal symptoms 8 (16.0)
Chest tightness 20 (40.0)
Gastrointestinal symptoms
Vomiting 9 (18.0)
Diarrhea 5 (10.0)
Single organ
Cutaneous system 25 (50.0)
Multiple organs
Cutaneous, respiratory system 14 (28.0)
Cutaneous, gastrointestinal system 4 (8.0)
Respiratory, gastrointestinal system 1 (2.0)
Cutaneous, respiratory, gastrointestinal system 6 (12.00)

Characteristics of the study population.

Data are presented as n (%) unless otherwise indicated.

SD, standard deviation.

a

Some patients reported >1 symptoms.

Diagnostic performance of different allergy tests

Oral challenges confirmed the diagnosis of shrimp allergy in 13 patients (26.0%). The results of SPT, sIgE to shrimp, and sIgE to tropomyosin are summarized in Table 2, and the diagnostic performance of each allergy test is reported in Table 3. From the total of 50 patients, 6 of the 13 patients (46.2%) who had a confirmed shrimp allergy diagnosis had positive SPT results. In the tolerant group, 18 of the 37 patients (48.7%) had positive SPT results. While these results indicate immunological sensitization, they were not associated with clinical reactivity following the oral food challenge using the specific shrimp material and dose protocol utilized in this study. The results of the SPT revealed that the sensitivity, specifically, PPV, and NPV were 46.2%, 51.4%, 25.0%, and 73.1%, respectively.

Table 2

Allergy testing and results Allergic group (n = 13) Tolerant group (n = 37) P-value
Skin prick test
 Positive 6 (46.2%) 18 (48.6%)
 Negative 7 (53.8%) 19 (51.4%)
Wheal size (mm)
 Median [IQR] 0 [0, 4.99] 2.65 [0, 4.72] 0.870
 Min–Max 0–12.46 0–10.20
sIgE to shrimp (f24)
 Positive 8 (61.5%) 21 (56.8%)
 Negative 5 (38.5%) 16 (43.2%)
Level (kUA/L)
 Median [IQR] 0.77 [0.16, 2.12] 0.58 [0.1, 2.35] 0.550
 Min–Max 0.04–33.5 0–36
sIgE to tropomyosin (f351)
 Positive 3 (23.1%) 3 (8.1%)
 Negative 10 (76.9%) 34 (91.9%)
Level (kUA/L)
 Median [IQR] 0.01 [0,0.08] 0.02 [0,0.04] 0.767
 Min–Max 0–5.05 0–2.34

Results of skin prick test, sIgE to shrimp, and sIgE to tropomyosin (N = 50).

IQR, interquartile range; SPT, skin prick test.

Table 3

Allergy testing Sensitivity (%) Specificity (%) PPV (%) NPV (%) Efficiency (%) AUC
Single test
Skin prick test (SPT) 46.2% 51.4% 25.0% 73.1% 50.0% 0.49 (0.32–0.65)
sIgE to shrimp 61.5% 43.2% 27.6% 76.2% 48.0% 0.52 (0.36–0.68)
sIgE to tropomyosin 23.1% 91.9% 50.0% 77.3% 74.0% 0.57 (0.45–0.70)
Combination testa
SPT, sIgE to shrimp 46.2% 70.3% 35.3% 78.8% 64.0% 0.58 (0.42–0.74)
SPT, sIgE to tropomyosin 23.1% 94.6% 60.0% 77.8% 76.0% 0.59 (0.46–0.71)
sIgE to shrimp, tropomyosin 23.1% 91.9% 50.0% 77.3% 74.0% 0.57 (0.45–0.70)

Diagnostic accuracy of skin prick test, sIgE to shrimp, or sIgE to tropomyosin alone and the combination of tests.

NPV, negative predictive value; PPV, positive predictive value; SPT, skin prick test.

a

Test positive was defined as positive to both tests.

Twenty-nine patients had levels of sIgE to shrimp ≥0.35 kUA/L; however, only eight subjects (27.6%) were confirmed to be allergic to shrimp by OFC. More than 50% of patients passed the OFC despite sIgE to shrimp ≥0.35 kUA/L. Wheal size from skin testing, sIgE to shrimp, and tropomyosin were not statistically different between the allergic and tolerant group (Supplementary Table S1). The sensitivity, specificity, PPV, and NPV of sIgE antibodies to shrimp were 61.5%, 43.2%, 27.6%, and 76.2%, respectively.

Three patients (23.1%) of the 13 positive OFC patients had positive levels of sIgE to rPen a 1 (≥0.35 kUA/L). Interestingly, among the 37 patients who could tolerate shrimp, 34 (91.9%) had negative sIgE to tropomyosin results. Only 3 (8.1%) patients appeared to have had false-negative test results as they developed reactions during the OFC. Hence, the specificity of sIgE to rPen a 1 from our findings was 91.9%, sensitivity of 23.1%, PPV of 50.0% for PPV, and NPV of 77.3%. We also evaluated alternative cutoff values for shrimp and tropomyosin-specific IgE, but none improved diagnostic performance. ROC analysis failed to identify a clinically meaningful threshold, as AUC values remained low and unchanged across different cutoffs, reflecting inherent limitations of these biomarkers rather than cutoff selection. Therefore, the conventional cutoff of ≥0.35 kUA/L was retained for consistency and comparability (Supplementary Tables S1, S2).

Finally, measurement of sIgE to tropomyosin gives the highest diagnostic efficiency (74.0%) followed by SPT (50.0%) and measurement of sIgE to shrimp (48.0%).

Diagnostic performance of SPT combined with sIgE to tropomyosin

Figure 1 shows the two-step diagnostic approach for shrimp allergy using SPT and sIgE level to tropomyosin. A total of 24 patients had positive results of SPT. When sIgE to tropomyosin was undertaken as the second test, 16 of 24 patients (66.7%) had positive results of SPT but had negative results of sIgE to tropomyosin in which all of 16 patients were tolerant to shrimp (negative OFC). Therefore, sIgE to tropomyosin is useful to decrease false-positive results for SPT in >50% of cases.

Figure 1

Flowchart illustrating the classification of fifty patients based on SPT and rPena1 results. Twenty-four patients are positive to SPT, and twenty-six are negative. Of those positive to SPT, five are positive to rPena1, leading to three positive and two negative to OFC. Nineteen are negative to rPena1, with three positive and sixteen negative to OFC. Among those negative to SPT, one is positive to rPena1 and negative to OFC. Twenty-five are negative to rPena1, with seven positive and eighteen negative to OFC.

Diagnostic performance of skin prick testing to shrimp commercial extract in the combination with specific IgE to tropomyosin (rPen a1) OFC, oral food challenge; rPen a1, recombinant Penaeus aztecus tropomyosin; SPT, skin prick testing.

The diagnostic performance of the combination of SPT and sIgE to tropomyosin is shown in Table 3. Test positive was defined as positive to both SPT and sIgE to tropomyosin. The combination of the test results improved the diagnostic performance of the specificity (94.6%) compared with either the SPT (51.4%) or sIgE to shrimp tropomyosin (91.9%) alone.

Diagnostic performance of sIgE to shrimp and sIgE to tropomyosin

The stepwise diagnostic approach algorithm for sIgE to shrimp and sIgE to tropomyosin is shown in Figure 2. From a total of 50 patients, 29 patients showed positive sIgE to shrimp. When sIgE to tropomyosin was undertaken as the second test, 18 of the 29 patients (62.1%) had negative results of sIgE to tropomyosin, and they were also tolerant to shrimp. Therefore, adding sIgE to tropomyosin as the second investigation decreases false-positive results for sIgE to shrimp. The specificity, sensitivity, PPV, and NPV after combining sIgE to shrimp and tropomyosin were 91.9%, 23.1%, 50.0%, and 77.3%, respectively (Table 3). Figure 3 also illustrates the receiver operating characteristic curve representing the distribution of area under the curve values for each single and combined diagnostic test.

Figure 2

Flowchart detailing a patient group of fifty analyzed for sensitivity. Twenty-nine are positive to sIgE, with six positive and twenty-three negative to rPena1. Among the positive rPena1, three are positive and three negative to OFC. Among the negative rPena1, five are positive and eighteen negative to OFC. Twenty-one are negative to sIgE and subsequently to rPena1, with none positive and all twenty-one negative to OFC.

Diagnostic performance of specific IgE to shrimp in the combination with specific IgE to tropomyosin (rPen a1) OFC, oral food challenge; rPen a1, recombinant Penaeus aztecus tropomyosin; SPT, skin prick testing.

Figure 3

ROC curve graph depicting sensitivity versus 1-specificity for various tests. Lines represent different tests: SPT, sIgE to shrimp, sIgE to tropomyosin, and combinations thereof. The ROC values range from 0.49 to 0.59, with the reference line indicating the baseline.

Receiver operating characteristic (ROC) curves illustrating the distribution area under curve values for each diagnostic test: sIgE, specific immunoglobulin E; SPT, skin prick testing.

Discussion

The diagnosis of shrimp allergy remains challenging despite its high prevalence. A key difficulty lies in the complex and species-specific variability of the major allergen, tropomyosin, which contributes to heterogeneity in IgE immune responses. Currently available diagnostic tools, including commercial skin prick testing (SPT) and serum shrimp-specific IgE (sIgE) assays (f24; ImmunoCAP), rely on crude shrimp extracts. The commercial shrimp extract used for SPT (ALK-Abello) is prepared from Litopenaeus setiferus, a prawn commonly found along the Atlantic coast. Meanwhile, the shrimp-specific IgE assay (f24 ImmunoCAP) contains a mixture of shrimp species, typically including Pandalus borealis (cold-water species) as well as Penaeus and Metapenaeus species (warm-water Indo-Pacific shrimp widely consumed worldwide). These extract-based tests primarily reflect sensitization rather than true clinical allergy and have limited ability to predict reactivity or reaction severity to specific shrimp species. Consequently, OFC with a defined shrimp species remains necessary for definitive diagnosis. To improve diagnostic accuracy, a multitiered approach is increasingly advocated. While sensitive crude extracts serve as effective screens, adding tropomyosin assessment (CRD) significantly enhances specificity and predicts clinical reactivity (14, 21, 22).

In the present study, sIgE to tropomyosin demonstrated the highest specificity, followed by SPT to commercial shrimp extract and whole shrimp sIgE. Diagnostic efficiency was also superior for sIgE to tropomyosin compared with the other modalities. In Thailand, tropomyosin has been identified as a major allergen among shrimp-allergic patients to both Penaeus monodon and Macrobrachium rosenbergii (23, 24). However, component sensitization patterns show geographic variability (21, 25–29). In European and some non-Asian cohorts, tropomyosin is not always the dominant component; instead, other components—such as sarcoplasmic calcium-binding protein (SCP), myosin light chain (Lit v 3), arginine kinase (AK), and other high-molecular-weight proteins—appear to play a more prominent role. In such settings, tropomyosin-specific IgE alone demonstrates lower diagnostic accuracy and is no longer considered a sufficient standalone biomarker (28–30). Therefore, the high specificity of sIgE to tropomyosin and its combination with SPT observed in our Thai cohort should be interpreted as context-specific and may not be directly generalizable to regions with different sensitization profiles.

Our results are consistent with previous studies. Yang et al. (22) reported that the specificity of sIgE to tropomyosin (92.8%) was greater than sIgE to shrimp (75%) and SPT to shrimp extract (64.2%). Serum IgE to tropomyosin had greater diagnostic efficiency (88.5%) compared with whole shrimp-specific IgE (74.2%) or SPT (65.7%). Wai et al. (31) reported low specificities of 28% and 35% for SPT and sIgE to shrimp, respectively, but the specificity of sIgE to rPen a 1 was 90%. Similarly, the results of Thalayasingam et al. (7) demonstrated that SPT using shrimp commercial extract and sIgE to shrimp had specificities of only 37% and 50%, respectively, but the specificity of sIgE to tropomyosin was 85.2%.

For this reason, component-resolved diagnostics (CRD) are recommended as a second-line test. Patients with positive SPT but negative component testing should undergo OFC to confirm or exclude true clinical allergy.

In conventional clinical practice, SPT is usually the first-line investigation. Patients with positive results are frequently advised to avoid shrimp without confirmatory testing. Although prick-to-prick testing using cooked shrimp has been shown to yield high specificity—up to 100% when performed with Penaeus monodon or Macrobrachium rosenbergii—there is a small but definite risk of systemic reactions (∼0.02%), particularly in high-risk patients (6). For this reason, component-resolved diagnostics (CRD) are recommended as a second-line test (32). Patients with positive SPT but negative component testing should undergo OFC to confirm or exclude true clinical allergy.

In our cohort, tropomyosin-specific IgE demonstrated superior specificity (91.9%) compared with extract-based tests; PPVs remained suboptimal (<50%), likely due to low disease prevalence (26%) and potential HDM cross-reactivity (Der p 10 was not assessed). However, combining SPT with sIgE to tropomyosin (rPen a 1) increased diagnostic specificity to 95%. In contrast, combining SPT with shrimp sIgE only modestly improved specificity (70.3%) and remained limited by low sensitivity (46.2%) and moderate NPV (78.8%). Clinically, this implies that nearly one-quarter of patients with negative results on both SPT and shrimp sIgE were still allergic by OFC. Therefore, this strategy cannot safely exclude shrimp allergy in patients with a convincing history. Our results support prior evidence that extract-based SPT and shrimp sIgE have limited predictive value and cannot replace OFC, particularly in high-suspicion cases (5, 7, 10, 16, 27).

The high specificity we observed for combined SPT and sIgE to tropomyosin suggests that this approach may be useful for reducing false-positive diagnoses and unnecessary dietary avoidance. However, it should be noted that our OFC protocol used a cumulative dose of 63 g of boiled shrimp (equivalent to approximately 15 g of shrimp protein), corresponding to a typical serving in Thailand. This dose lies at the lower end of the recommended 15–20 g range (20). Testing with lower challenge doses may increase the risk of false-negative results in individuals with higher reaction thresholds or those requiring specific co-factors (e.g., exercise and NSAIDs) to elicit symptoms. Thus, residual misclassification cannot be completely excluded.

A critical limitation observed across all diagnostic modalities in our study—including SPT, extract-sIgE, and tropomyosin sIgE—was the uniformly poor sensitivity and negative predictive values (NPV). Specifically, tropomyosin sIgE showed a sensitivity of only 23%, meaning it failed to identify nearly 80% of true allergy cases. This finding is in line with an Italian multicenter study, which reported Pen a 1 sensitization in 41% of shrimp-allergic adults (25). The low sensitivity of tropomyosin highlights the relevance of ‘context-specific’ allergen profiles. Sensitization patterns vary significantly by geography and consumption habits. While tropomyosin is often the major allergen in mite-sensitized populations, our data suggest that our cohort may be predominantly sensitized to other heat-stable or labile components not captured by this single test. Minor allergens such as AK, SCP, and myosin light chain are increasingly recognized as clinically relevant triggers, particularly in Asian populations (21, 24, 26–28). Recent studies further indicate that tropomyosin alone is insufficient as a diagnostic marker; recent studies indicate that combining multiple recombinant components (e.g., AK and SCP alongside tropomyosin) can significantly improve diagnostic sensitivity (29). Future research should therefore focus on evaluating multicomponent panels for more accurate diagnosis and tailored to local sensitization profiles to reduce the reliance on OFC.

Several limitations must be acknowledged. First, we employed an open OFC design rather than a double-blind, placebo-controlled OFC, which is considered the gold standard. However, the open method is more feasible in routine practice, and we minimized bias by defining positivity based on objective clinical signs. Moreover, nurses and allergists conducting the OFC were blinded to all index test results. Second, there was a species mismatch between diagnostic tests and the challenge material. The commercial SPT and f24 ImmunoCAP extracts contain mixed shrimp species (e.g., P. monodon, M. barbata, P. borealis, M. joyneri), whereas the OFC used Litopenaeus vannamei. Additionally, the tropomyosin assay employed recombinant Pen a 1 from P. aztecus. In silico analysis by Soto-Muñoz et al. (33) showed very high amino acid sequence identity (95%–100%) between tropomyosin from L. vannamei and P. aztecus, supporting the potential for IgE cross-reactivity. Nevertheless, sequence homology does not guarantee identical allergen expression or clinical relevance, and this remains a methodological limitation. Third, due to the retrospective nature of clinical history taking, the specific shrimp species responsible for the index reaction could not be reliably determined. Given the recognized phenomenon of species-specific prawn allergy, this limitation may partly explain discordance between clinical history and OFC results. Finally, the relatively small number of OFC-positive patients (n = 13) reduces statistical precision and results in wider confidence intervals for sensitivity, PPV, and NPV estimates. These findings therefore require confirmation in larger prospective studies.

In conclusion, conventional diagnostic tools for shrimp allergy—SPT and shrimp sIgE—demonstrate low specificity and limited clinical utility. Measurement of tropomyosin-specific IgE offers significantly higher specificity and improved diagnostic efficiency, either alone or when combined with SPT. This approach may reduce false-positive diagnoses and unnecessary dietary restriction, although OFC remains essential for definitive diagnosis, particularly in patients with compatible clinical histories.

Statements

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving humans were approved by the Human Research Ethics Committee of Thammasat University (Medicine). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

Author contributions

PKu: Formal analysis, Writing – original draft, Visualization, Conceptualization, Project administration, Writing – review & editing, Data curation, Methodology, Investigation. PKr: Methodology, Writing – review & editing, Writing – original draft, Conceptualization. SP: Conceptualization, Supervision, Methodology, Writing – review & editing, Writing – original draft. OJ: Supervision, Writing – review & editing, Conceptualization, Writing – original draft, Methodology. NA: Writing – original draft, Project administration, Data curation, Writing – review & editing. NK: Writing – original draft, Data curation, Writing – review & editing. OP: Writing – review & editing, Writing – original draft. SN: Validation, Writing – review & editing, Investigation, Visualization, Formal analysis, Supervision, Conceptualization, Writing – original draft.

Funding

The author(s) declared that financial support was received for this work and/or its publication. This study was funded by the National Research Council of Thailand.

Acknowledgments

We would like to thank Junprateepsuda Dulpinijthamma, M.D., for assistance in data collection and Woraphorn Fukpho, Medical Technology Laboratory of Thammasat University Hospital, Pathum Thani, Thailand, for assistance in laboratory testing.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence, and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/falgy.2026.1737009/full#supplementary-material

References

  • 1.

    Gupta RS Warren CM Smith BM Jiang J Blumenstock JA Davis MM et al Prevalence and severity of food allergies among US adults. JAMA Netw Open. (2019) 2:e185630. 10.1001/jamanetworkopen.2018.5630

  • 2.

    Wai CYY Leung NYH Leung ASY Wong GWK Leung TF . Seafood allergy in Asia: geographical specificity and beyond. Front Allergy. (2021) 2:676903. 10.3389/falgy.2021.676903

  • 3.

    Warren CM Aktas ON Gupta RS Davis CM . Prevalence and characteristics of adult shellfish allergy in the United States. J Allergy Clin Immunol. (2019) 144:1435–8.E5. 10.1016/j.jaci.2019.07.031

  • 4.

    Wang HT Warren CM Gupta RS Davis CM . Prevalence and characteristics of shellfish allergy in the pediatric population of the United States. J Allergy Clin Immunol Pract. (2020) 8:1359–70.e2. 10.1016/j.jaip.2019.12.027

  • 5.

    Davis CM Gupta RS Aktas ON Diaz V Kamath SD Lopata AL . Clinical management of seafood allergy. J Allergy Clin Immunol Pract. (2020) 8:37–44. 10.1016/j.jaip.2019.10.019

  • 6.

    Jirapongsananuruk O Sripramong C Pacharn P Udompunturak S Chinratanapisit S Piboonpocanun S et al Specific allergy to Penaeus monodon (seawater shrimp) or Macrobrachium rosenbergii (freshwater shrimp) in shrimp-allergic children. Clin Exp Allergy. (2008) 38:1038–47. 10.1111/j.1365-2222.2008.02979.x

  • 7.

    Thalayasingam M Gerez IF Yap GC Llanora GV Chia IP Chua L et al Clinical and immunochemical profiles of food challenge proven or anaphylactic shrimp allergy in tropical Singapore. Clin Exp Allergy. (2015) 45:687–97. 10.1111/cea.12416

  • 8.

    Wong DSH Santos AF . The future of food allergy diagnosis. Front Allergy. (2024) 5:1456585. 10.3389/falgy.2024.1456585

  • 9.

    Maesa JM Dobrzynska A Banos-Alvarez E Isabel-Gomez R Blasco-Amaro JA . ImmunoCAP ISAC in food allergy diagnosis: a systematic review of diagnostic test accuracy. Clin Exp Allergy. (2021) 51:778–89. 10.1111/cea.13871

  • 10.

    Wai CYY Leung NYH Chu KH Leung PSC Leung ASY Wong GWK et al Overcoming shellfish allergy: how far have we come? Int J Mol Sci. (2020) 21:2234. 10.3390/ijms21062234

  • 11.

    Tong WS Yuen AW Wai CY Leung NY Chu KH Leung PS . Diagnosis of fish and shellfish allergies. J Asthma Allergy. (2018) 11:247–60. 10.2147/JAA.S142476

  • 12.

    Leung PS Chow WK Duffey S Kwan HS Gershwin ME Chu KH . IgE reactivity against a cross-reactive allergen in crustacea and mollusca: evidence for tropomyosin as the common allergen. J Allergy Clin Immunol. (1996) 98:954–61. 10.1016/S0091-6749(96)80012-1

  • 13.

    Martinez D Fang L Meza-Torres C Garavito G Lopez-Lluch G Egea E . Toward consensus epitopes B and T of tropomyosin involved in cross-reactivity across diverse allergens: an in silico study. Biomedicines. (2024) 12:884. 10.3390/biomedicines12040884

  • 14.

    Gámez C Sanchez-Garcia S Ibanez MD Lopez R Aguado E Lopez E et al Tropomyosin IgE-positive results are a good predictor of shrimp allergy. Allergy. (2011) 66:1375–83. 10.1111/j.1398-9995.2011.02663.x

  • 15.

    Ayuso R Sanchez-Garcia S Pascal M Lin J Grishina G Fu Z et al Is epitope recognition of shrimp allergens useful to predict clinical reactivity? Clin Exp Allergy. (2012) 42:293–304. 10.1111/j.1365-2222.2011.03920.x

  • 16.

    Wong L Huang CH Lee BW . Shellfish and house dust mite allergies: is the link tropomyosin?Allergy Asthma Immunol Res. (2016) 8:101–6. 10.4168/aair.2016.8.2.101

  • 17.

    Kulalert P Poachanukoon O Nanthapisal S Sritipsukho P Thanborisutkul K Termworasin P et al Minimum number and types of allergens for a skin prick test panel in Thai children with allergic respiratory diseases. Allergy Asthma Clin Immunol. (2022) 18:77. 10.1186/s13223-022-00718-7

  • 18.

    Jarupalee T Chatchatee P Komolpis K Suratannon N Roytrakul S Yingchutrakul Y et al Detecting allergens from black tiger shrimp Penaeus monodon that can bind and cross-link IgE by ELISA, western blot, and a humanized rat basophilic leukemia reporter cell line RS-ATL8. Allergy Asthma Immunol Res. (2018) 10:62–76. 10.4168/aair.2018.10.1.62

  • 19.

    Sampson HA Aceves S Bock SA James J Jones S Lang D et al Food allergy: a practice parameter update-2014. J Allergy Clin Immunol. (2014) 134:1016–25.e43. 10.1016/j.jaci.2014.05.013

  • 20.

    Sampson HA Arasi S Bahnson HT Ballmer-Weber B Beyer K Bindslev-Jensen C et al AAAAI-EAACI PRACTALL: standardizing oral food challenges-2024 update. Pediatr Allergy Immunol. (2024) 35:e14276. 10.1111/pai.14276

  • 21.

    Pascal M Grishina G Yang AC Sanchez-Garcia S Lin J Towle D et al Molecular diagnosis of shrimp allergy: efficiency of several allergens to predict clinical reactivity. J Allergy Clin Immunol Pract. (2015) 3:521–9.e10. 10.1016/j.jaip.2015.02.001

  • 22.

    Yang AC Arruda LK Santos AB Barbosa MC Chapman MD Galvao CE et al Measurement of IgE antibodies to shrimp tropomyosin is superior to skin prick testing with commercial extract and measurement of IgE to shrimp for predicting clinically relevant allergic reactions after shrimp ingestion. J Allergy Clin Immunol. (2010) 125:872–8. 10.1016/j.jaci.2009.11.043

  • 23.

    Kumjim S Jirapongsananuruk O Piboonpocanun S . Cloning and characterization of recombinant tropomyosin of giant freshwater shrimp M. rosenbergii to determine major allergens causing allergic reactions among shrimp-allergic children. Asian Pac J Allergy Immunol. (2016) 34:229–35. 10.12932/AP0698

  • 24.

    Wai CYY Leung NYH Leung ASY Ngai SM Pacharn P Yau YS et al Comprehending the allergen repertoire of shrimp for precision molecular diagnosis of shrimp allergy. Allergy. (2022) 77:3041–51. 10.1111/all.15370

  • 25.

    Asero R Mistrello G Amato S Ariano R Colombo G Conte ME et al Shrimp allergy in Italian adults: a multicenter study showing a high prevalence of sensitivity to novel high molecular weight allergens. Int Arch Allergy Immunol. (2012) 157:3–10. 10.1159/000324470

  • 26.

    Ayuso R Grishina G Bardina L Carrillo T Blanco C Ibanez MD et al Myosin light chain is a novel shrimp allergen, Lit v 3. J Allergy Clin Immunol. (2008) 122:795–802. 10.1016/j.jaci.2008.07.023

  • 27.

    Faber MA Pascal M El Kharbouchi O Sabato V Hagendorens MM Decuyper II et al Shellfish allergens: tropomyosin and beyond. Allergy. (2017) 72:842–8. 10.1111/all.13115

  • 28.

    Garcia-Orozco KD Aispuro-Hernandez E Yepiz-Plascencia G Calderon-de-la-Barca AM Sotelo-Mundo RR . Molecular characterization of arginine kinase, an allergen from the shrimp Litopenaeus vannamei. Int Arch Allergy Immunol. (2007) 144:23–8. 10.1159/000102610

  • 29.

    Grilo J Vollmann U Aumayr M Sturm GJ Bohle B . Tropomyosin is no accurate marker allergen for diagnosis of shrimp allergy in central Europe. Allergy. (2022) 77:1921–3. 10.1111/all.15290

  • 30.

    Karnaneedi S Anvari S Brunner S Tuano KS Su BB Hira S et al Shrimp allergy-distinct allergen sensitization profiles between intercontinental cohorts. Allergy. (2025) 80:2909–13. 10.1111/all.16662

  • 31.

    Wai CYY Leung NYH Leung ASY Shum Y Leung PSC Chu KH et al Cell-based functional IgE assays are superior to conventional allergy tests for shrimp allergy diagnosis. J Allergy Clin Immunol Pract. (2021) 9:236–44.e9. 10.1016/j.jaip.2020.08.057

  • 32.

    Foong RX Dantzer JA Wood RA Santos AF . Improving diagnostic accuracy in food allergy. The Journal of Allergy and Clinical Immunology in Practice. (2021) 9:71–80. 10.1016/j.jaip.2020.09.037

  • 33.

    Soto-Muñoz A Rodríguez-Canul R . In silico analysis of the cross-reactivity of Pacific white shrimp (Litopenaeus vannamei) allergens with other arthropod Species. Open J Immunol. (2022) 12:15–39. 10.4236/oji.2022.121002

Summary

Keywords

component-resolved diagnosis, diagnosis accuracy, oral food challenge, shrimp allergy, tropomyosin (TPM)

Citation

Kulalert P, Kreetapirom P, Piboonpocanun S, Jirapongsananuruk O, Authong N, Khodtecha N, Poachanukoon O and Nanthapisal S (2026) Specific IgE to tropomyosin increases the diagnostic accuracy of shrimp allergy. Front. Allergy 7:1737009. doi: 10.3389/falgy.2026.1737009

Received

31 October 2025

Revised

27 December 2025

Accepted

05 January 2026

Published

23 January 2026

Volume

7 - 2026

Edited by

Bee Wah Lee, National University of Singapore, Singapore

Reviewed by

Agnes Leung, The Chinese University of Hong Kong, China

Lydia Wong, National University Health System, Singapore

Updates

Copyright

* Correspondence: Sira Nanthapisal

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics